AUG 18, 2026 · JOURNAL ARTICLE
Circulatory and other-cause mortality after neoadjuvant versus adjuvant chemotherapy in women with stage II–III breast cancer
Biomolecules and Biomedicine
A large, well-designed retrospective cohort study with robust methods (inverse-probability weighting, competing-risks analysis) that confirms the absence of a clinically meaningful difference in circulatory mortality between treatment sequences, with narrow confidence intervals crossing the null.
Important Confirmatory EvidenceMehmet Zafer SabuncuoğluLymphatic System and DiseasesCancer Risks and Factors
Reported
Sample size74233
Median follow-up10.8 years
10-year cumulative incidence of c…2.06%